Skip NavigationSkip to Content
Return Return to Search Results

Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy

  1. Author:
    Mena, Esther [ORCID]
    Lindenberg, Maria L
    Shih, Joanna H
    Adler, Stephen
    Harmon, Stephanie
    Bergvall, Ethan
    Citrin, Deborah
    Dahut, William
    Ton, Anita T
    McKinney, Yolanda
    Weaver, Juanita
    Eclarinal, Philip
    Forest, Alicia
    Afari, George
    Bhattacharyya, Sibaprasad
    Mease, Ronnie C
    Merino, Maria J
    Pinto, Peter
    Wood, Bradford J
    Jacobs, Paula
    Pomper, Martin G
    Choyke, Peter L
    Turkbey, Baris

  2. Author Address

    Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA. esther.menagonzalez@nih.gov., Division of Cancer treatment and Diagnosis: Biometric Research Program, National Cancer Institute, NIH, Bethesda, MD, USA., Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute, Campus at Frederick, Frederick, MD, USA., Radiation Oncology Branch, Center for Cancer Research. National Cancer Institute, NIH, Bethesda, MD, USA., Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, USA., Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA., Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA., Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA., Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Cancer Institute, NIH, Bethesda, MD, USA., Cancer Imaging Program, National Cancer Institute, NIH, Rockville, MD, USA.,
    1. Year: 2018
    2. Date: Jan
    3. Epub Date: 2017 Sep 11
  2. Journal: European Journal of Nuclear Medicine and Molecular Imaging
    1. 45
    2. 1
    3. Pages: 4-11
  4. Type of Article: Article
  5. ISSN: 1619-7070
  1. Abstract:

    The purpose of our study was to assess (18)F-DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment. This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging. All 68 patients underwent whole-body (18)F-DCFBC PET/CT, and 62 also underwent mpMRI within one month. Lesion detection with (18)F-DCFBC was correlated with mpMRI findings and pre-scan PSA levels. The impact of (18)F-DCFBC PET/CT on clinical management and treatment decisions was established after 6 months' patient clinical follow-up. Forty-one patients (60.3%) showed at least one positive (18)F-DCFBC lesion, for a total of 79 lesions, 30 in the prostate bed, 39 in lymph nodes, and ten in distant sites. Tumor recurrence was confirmed by either biopsy (13/41 pts), serial CT/MRI (8/41) or clinical follow-up (15/41); there was no confirmation in five patients, who continue to be observed. The (18)F-DCFBC and mpMRI findings were concordant in 39 lesions (49.4%), and discordant in 40 lesions (50.6%); the majority (n = 32/40) of the latter occurring because the recurrence was located outside the mpMRI field of view. (18)F-DCFBC PET positivity rates correlated with PSA values and 15%, 46%, 83%, and 77% were seen in patients with PSA values < 0.5, 0.5 to < 1.0, 1.0 to < 2.0, and =2.0 ng/mL, respectively. The optimal cut-off PSA value to predict a positive (18)F-DCFBC scan was 0.78 ng/mL (AUC = 0.764). A change in clinical management occurred in 51.2% (21/41) of patients with a positive (18)F-DCFBC result, generally characterized by starting a new treatment in 19 patients or changing the treatment plan in two patients. (18)F-DCFBC detects recurrences in 60.3% of a population of patients with biochemical recurrence, but results are dependent on PSA levels. Above a threshold PSA value of 0.78 ng/mL, (18)F-DCFBC was able to identify recurrence with high reliability. Positive (18)F-DCFBC PET imaging led clinicians to change treatment strategy in 51.2% of patients.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/s00259-017-3818-x
  3. PMID: 28894899
  4. View record in Web of Science®
  5. WOS: 000416151400002

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel